-
Mashup Score: 93
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 76
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. @US_FDA approves NEW #ALK inhibitor (#Ensartinib) for 1st line Tx of advanced #ALK+ #NSCLC Approval based on #eXALT3 trial of #Ensartinib vs #Crizotinib. ⬆️ #mPFS: 25.8 vs 12.7 months (HR: 0.56). No #OS difference 👇🏼 https://t.co/CXnlyvY79B https://t.co/IbmJsNruqZ
-
-
Mashup Score: 74
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. @US_FDA approves NEW #ALK inhibitor (#Ensartinib) for 1st line Tx of advanced #ALK+ #NSCLC Approval based on #eXALT3 trial of #Ensartinib vs #Crizotinib. ⬆️ #mPFS: 25.8 vs 12.7 months (HR: 0.56). No #OS difference 👇🏼 https://t.co/CXnlyvY79B https://t.co/IbmJsNruqZ
-
-
Mashup Score: 74
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. @US_FDA approves NEW #ALK inhibitor (#Ensartinib) for 1st line Tx of advanced #ALK+ #NSCLC Approval based on #eXALT3 trial of #Ensartinib vs #Crizotinib. ⬆️ #mPFS: 25.8 vs 12.7 months (HR: 0.56). No #OS difference 👇🏼 https://t.co/CXnlyvY79B https://t.co/IbmJsNruqZ
-
-
Mashup Score: 94
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
🚨🔥 1/2 @OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation on updated data @myESMO #ESMO2024 Results of #ADRIATIC trial of #Durvalumab vs #Placebo after #Chemoradiotherapy in Limited-Stage #SmallCell #LungCancer. 👇🏼 https://t.co/ElbWrwddii https://t.co/c6DTq1DORo
-
-
Mashup Score: 47FDA approves durvalumab for limited-stage small cell lung cancer - 6 month(s) ago
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. As anticipated; @US_FDA approved #Durvalumab after #Chemoradiotherapy limited stage #SmallCell #LungCancer. Approval is based on PRACTICE CHANGING #Adriatic Trial ✅Impressive ⬆️ #mOS (55.9 vs 33.4 months HR: 0.73) 👇🏼 https://t.co/MdcTavgZj7 https://t.co/neRccaWjiN https://t.co/5CkYjvj7YG
-
-
Mashup Score: 47FDA approves durvalumab for limited-stage small cell lung cancer - 6 month(s) ago
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. As anticipated; @US_FDA approved #Durvalumab after #Chemoradiotherapy limited stage #SmallCell #LungCancer. Approval is based on PRACTICE CHANGING #Adriatic Trial ✅Impressive ⬆️ #mOS (55.9 vs 33.4 months HR: 0.73) 👇🏼 https://t.co/MdcTavgZj7 https://t.co/neRccaWjiN https://t.co/5CkYjvj7YG
-
-
Mashup Score: 47FDA approves durvalumab for limited-stage small cell lung cancer - 6 month(s) ago
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. As anticipated; @US_FDA approved #Durvalumab after #Chemoradiotherapy limited stage #SmallCell #LungCancer. Approval is based on PRACTICE CHANGING #Adriatic Trial ✅Impressive ⬆️ #mOS (55.9 vs 33.4 months HR: 0.73) 👇🏼 https://t.co/MdcTavgZj7 https://t.co/neRccaWjiN https://t.co/5CkYjvj7YG
-
-
Mashup Score: 47FDA approves durvalumab for limited-stage small cell lung cancer - 6 month(s) ago
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. As anticipated; @US_FDA approved #Durvalumab after #Chemoradiotherapy limited stage #SmallCell #LungCancer. Approval is based on PRACTICE CHANGING #Adriatic Trial ✅Impressive ⬆️ #mOS (55.9 vs 33.4 months HR: 0.73) 👇🏼 https://t.co/MdcTavgZj7 https://t.co/neRccaWjiN https://t.co/5CkYjvj7YG
-
-
Mashup Score: 82Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis - 6 month(s) ago
This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based on the time between diagnosis and program entry.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Not all #Patients with #Cancer have smoked but for those who have, #SmokingCessation improves ⬆️survival (& the earlier the better). 🔥🚨@OncoAlert Just published @JAMAOnc #Survival Outcomes of #Smoking #Cessation Treatment After Cancer Diagnosis. 👇🏼 https://t.co/1l4QwqQoWV https://t.co/jq4v327jvI
-
🚨🔥 1/2 @OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation on updated data @myESMO #ESMO2024 Results of #ADRIATIC trial of #Durvalumab vs #Placebo after #Chemoradiotherapy in Limited-Stage #SmallCell #LungCancer. 👇🏼 https://t.co/ElbWrwddii https://t.co/c6DTq1DORo